Three Doses of TAS-108 to Treat Recurrent or Recurrent Inoperable Breast Cancer

Breast Cancer Clinical Trial

Official title:

A Phase II, Randomized, Double-Blinded Efficacy and Safety Study of Three Doses of TAS-108 Administered Orally in Postmenopausal Patients With Locally Advanced or Locally Recurrent Inoperable or Progressive Metastatic Breast Cancer Following Standard First-Line Endocrine Therapy

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00166543
• Other study ID #: 2216-03
• Secondary ID: TAS108-0004
• Status: Completed
• Phase: Phase 2
• First received: September 12, 2005
• Last updated: July 28, 2015
• Start date: May 2004
• Est. completion date: January 2008

Study information

• Verified date: June 2015
• Source: SRI International
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

This study is being done to find out how safe TAS-108 is and how well TAS-108 works on recurrent or recurrent inoperable breast cancer.

Description:

The objective of this study is to investigate the efficacy and safety of TAS-108 administered in postmenopausal patients with locally advanced or locally recurrent inoperable or progressive metastatic breast carcinoma who have previously responded to one or two standard endocrine therapies, with or without one prior chemotherapy.

Other known NCT identifiers

• NCT00687557

Recruitment information / eligibility

• Status: Completed
• Enrollment: 146
• Est. completion date: January 2008
• Est. primary completion date: January 2008
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Postmenopausal females

• Histologically or cytologically confirmed diagnosis of breast carcinoma

• Locally advanced or locally recurrent inoperable or metastatic breast carcinoma with documented disease progression

• Has laboratory documentation of positive estrogen receptor (ER) and/or progesterone receptor (PgR) status, and has responded to the standard first or second line hormonal anti-tumor therapy given

• Has received and whose disease progressed after one or two prior systemic hormonal anti-tumor therapies

• Performance status of greater than or equal to 2 on the Zubrod scale

• Predicted life expectancy of greater than or equal to 12 weeks

• Must give written informed consent

• Measurable disease according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria

• Absolute granulocyte count of greater than 1,500/meqL, platelet count greater than 75,000/meqL, and a hemoglobin of greater than 10 g/dL

• Adequate liver and renal function as defined by a bilirubin of less than 1.5 times the upper limit of normal and a creatinine of less than 1.5 times the upper limit of normal

• Transaminases must be less than 2.5 times the upper limit of normal except for patients with liver metastases who may have transaminases less than 5 times the upper limit of normal.

• The patient has recovered from all previous anti-cancer treatment related to toxicities to at least Grade 1.

• All previous investigational drugs must be stopped at least four weeks before commencement of treatment with TAS-108.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Breast Cancer
• Breast Neoplasms

Intervention

Drug:
• TAS-108

Locations

Country	Name	City	State
United States	Mayo Clinic	Rochester	Minnesota

Sponsors (2)

Lead Sponsor	Collaborator
SRI International	Taiho Pharmaceutical Co., Ltd.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To evaluate the safety of TAS-108 administered on this schedule	Treatment-emergent adverse events, serious adverse events, bone mineral density	Up to 4 years and 3 months	Yes
Primary	To investigate the comparative concentrations of TAS-108 and its metabolites in tumor tissue and blood at steady-state		Up to 4 years and 3 months	No
Primary	To determine the time to progression of TAS-108 administered on this schedule		Up to 4 years and 3 months	No